Loading stock data…
Tarsus Pharmaceuticals, Inc. (TARS)
$61.26-1.66 (-2.64%)
Market ClosedLast close Jun 29
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tarsus Pharmaceuticals, Inc. in the Healthcare sector is trading at $61.26 with a market capitalization of $2.5B. Wall Street consensus targets $94.11 (9 analysts), implying a +53.6% move over the next 12 months. The stock is currently 28% below its 52-week high of $85.25, remaining 10.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +53.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $162.05M↑ | $151.67M↑ | $118.70M↑ | $102.66M↑ | $78.33M |
| Gross Profit | $152.66M↑ | $140.74M↑ | $110.39M↑ | $96.42M↑ | $73.12M |
| Operating Income | -$6.12M↑ | -$7.98M↑ | -$14.53M↑ | -$22.18M↑ | -$26.28M |
| Net Income | -$6.97M↑ | -$8.37M↑ | -$12.59M↑ | -$20.34M↑ | -$25.12M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.53B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.83%
Volume
Today's trading volume
956,109
Recent News
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
A Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived Discount
Stock performance snapshot and recent returns Tarsus Pharmaceuticals (TARS) has drawn investor attention after recent share price moves, with the stock up 3.2% over the past day and 7.2% over the past week, despite a softer past 3 months. Over the past month the stock is roughly flat, while over the past 3 months it has declined 11.9%. Year to date, the share price is down 23.8%, reflecting a last close of US$61.55 and a market value of about US$2.57b. See our latest analysis for Tarsus...
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.